

Help prevent RSV-LRTI

Consider Beyfortus® for infants year-round based on regional RSV circulation in Florida¹

Florida's RSV season is longer than the rest of the US and has distinct regional patterns¹

Florida's RSV season varies by region, with different regions having distinct onset and peak times. For this reason, the state is broken up into 5 RSV regions, each with its own RSV season.^{1,2*}

Beyfortus is available through the Vaccines for Children Program (VFC), Medicaid plans, and most private health insurance plans.^{3†}

IMMUNIZE throughout the
ELIGIBLE INFANTS year with Beyfortus¹

RSV-LRTI, respiratory syncytial virus lower respiratory tract infection.

*The RSV season by region: Northwest Florida (October to April), North Florida (September to March), Central Florida (August to March), Southeast Florida (January to December), and Southwest Florida (September to April).¹

†Based on available information from national payer organizations.

INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Please see additional Important Safety Information on the following page and accompanying full Prescribing Information.

 **Beyfortus®** | 50 mg
(nirsevimab-alip) | 100 mg
Injection

Help protect infants against RSV disease with Beyfortus®⁴

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions

- **Hypersensitivity Reactions Including Anaphylaxis:** Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
- **Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see accompanying full Prescribing Information.

Contact your wholesaler or distributor for further details on indirect ordering



References: **1.** Florida RSV review season: 2024-2025. Florida Department of Health. August 17, 2025-August 23, 2025. Accessed September 25, 2025. https://www.floridahealth.gov/diseases-and-conditions/respiratory-illness/respiratory-syncytial-virus/_documents/2025-w35-rsv-summary.pdf **2.** Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(34):920-925. **3.** CDC's Vaccines for Children Program addendum: special considerations for COVID-19 vaccine and nirsevimab. Centers for Disease Control and Prevention. Updated March 29, 2024. Accessed September 25, 2025. https://www.cdc.gov/vaccines-for-children/media/pdfs/2024/08/operations-guide-covid-19-addendum-2024-4-2_002-508.pdf **4.** Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi.

sanofi

1 Discovery Drive, Swiftwater, PA 18370
© 2025 Sanofi. All rights reserved.
MAT-US-2511516-v1.0-10/2025

 **Beyfortus®** | 50 mg
(nirsevimab-alip) | 100 mg
Injection